Krankenhaus Der Barmherzigen Brueder Wien
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department is conducting studies on acute ischemic stroke to assess novel therapeutic regimens that aim to improve survival and reduce severe adverse events.
- Acute Ischemic Stroke
- Safety profiling of chemotherapy combinations in patients with vascular risk factors
- Comparative dosing strategies for docetaxel in metastatic hormone‑sensitive prostate cancer
Research at Krankenhaus Der Barmherzigen Brueder Wien integrates cardiovascular risk assessment into oncology protocols to enhance overall patient safety.
Digestive System Diseases
Clinical trials focus on inflammatory bowel disorders and liver‑related malignancies, evaluating new biologics, combination therapies, and maintenance approaches to achieve durable remission.
- Crohn's Disease
- Moderately to severely active Ulcerative Colitis
- Primary Biliary Cholangitis
- Hepatocellular Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
The Department of Internal Medicine I leverages a multidisciplinary framework to test innovative agents such as risankizumab, vedolizumab, and upadacitinib.
Immune System Diseases
Trials explore immune‑modulating strategies, including checkpoint inhibition and combination immunotherapy, to improve outcomes in both cancer and autoimmune contexts.
- Muscle‑invasive bladder cancer with immunotherapy‑based regimens
- Advanced solid tumors receiving zanzalintinib plus nivolumab‑based combinations
- Immune checkpoint inhibitor therapies for urothelial carcinoma
- Immunomodulatory treatment for primary biliary cholangitis
Researchers at the site aim to refine immune checkpoint strategies that could broaden therapeutic options across multiple disease spectrums.
Male Urogenital Diseases
The focus is on prostate and bladder malignancies, testing hormonal agents, antibody‑drug conjugates, and radiation‑combined approaches to extend survival and delay disease progression.
- Metastatic Castration‑Resistant Prostate Cancer
- Metastatic Castration‑Sensitive Prostate Cancer
- Urothelial Carcinoma (bladder cancer)
- Clear cell and non‑clear cell Renal Cell Carcinoma
- Locally advanced or metastatic urothelial cancer
Studies such as the ARASAFE trial and BT8009‑230 evaluate novel combinations to improve outcomes for patients with these urogenital cancers.
Neoplasms
A broad oncology portfolio addresses solid tumors ranging from colorectal to lung and head‑and‑neck cancers, emphasizing targeted agents, combination regimens, and survival endpoints.
- Colorectal Cancer
- Non‑Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Clear cell Renal Cell Carcinoma
- Hepatocellular Cancer
The site’s oncology program seeks to demonstrate efficacy of agents like zelenectide pevedotin and AZD5305 in improving progression‑free and overall survival.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Janssen Cilag International3active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International5trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Krankenhaus Der Barmherzigen Brueder Wien
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 48 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Gemcitabine | 5 | Unknown | 2022-11-11 | 2025-11-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.